ANRO · Insider Trading
Alto Neuroscience Inc.
Every open-market purchase and sale reported by ANRO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Nicholas Conrad Smith | PRESIDENT AND CFO | M | +55,000 | +$127.60K |
| 2026-10-01 | Nicholas Conrad Smith | PRESIDENT AND CFO | MIXED | — | −$3.25M |
| 2026-05-29 | Andrew Craig Miller | Director | A | +26,000 deriv. | — |
| 2026-05-15 | Amit Etkin | PRESIDENT AND CEO | G | −400,000 | — |
| 2026-05-14 | Andrew Dreyfus | Director | A | +10,958 deriv. | — |
| 2026-05-14 | Husseini Manji | Director | A | +10,958 deriv. | — |
| 2026-05-14 | Ramiro Sanchez | Director | A | +10,958 deriv. | — |
| 2026-05-14 | Gwill York | Director | A | +10,958 deriv. | — |
| 2026-05-14 | Christopher Nixon Cox | Director | A | +10,958 deriv. | — |
| 2026-03-03 | Amit Etkin | PRESIDENT AND CEO | F | −6,227 | −$122.61K |
| 2026-03-03 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | F | −2,806 | −$55.25K |
| 2026-02-13 | Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | A | +131,000 deriv. | — |
| 2026-02-13 | Adam Savitz | CHIEF MEDICAL OFFICER | A | +124,000 deriv. | — |
| 2026-02-13 | Amit Etkin | PRESIDENT AND CEO | A | +306,000 deriv. | — |
| 2026-02-13 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | A | +200,000 deriv. | — |
| 2026-01-06 | Christopher Nixon Cox | Director | A | +7,189 deriv. | — |
| 2026-01-06 | Ramiro Sanchez | Director | A | +3,806 deriv. | — |
| 2026-01-06 | Husseini Manji | Director | A | +4,228 deriv. | — |
| 2026-01-06 | Gwill York | Director | A | +5,243 deriv. | — |
| 2025-08-14 | Ramiro Sanchez | Director | A | +34,502 deriv. | — |
| 2025-07-08 | Amit Etkin | PRESIDENT AND CEO | MIXED | — | — |
| 2025-07-08 | Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2025-07-08 | Adam Savitz | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-07-08 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | MIXED | — | — |
| 2025-05-15 | Christopher Nixon Cox | Director | A | +15,287 deriv. | — |
| 2025-05-15 | Andrew Dreyfus | Director | A | +15,287 deriv. | — |
| 2025-05-15 | Gwill York | Director | A | +15,287 deriv. | — |
| 2025-05-15 | Husseini Manji | Director | A | +15,287 deriv. | — |
| 2025-02-07 | Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | A | +125,000 deriv. | — |
| 2025-02-07 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | A | +135,000 deriv. | — |
| 2025-02-07 | Amit Etkin | PRESIDENT AND CEO | A | +215,000 deriv. | — |
| 2025-02-07 | Adam Savitz | CHIEF MEDICAL OFFICER | A | +76,000 deriv. | — |
| 2025-01-06 | Husseini Manji | Director | A | +14,195 deriv. | — |
| 2025-01-06 | Gwill York | Director | A | +19,558 deriv. | — |
| 2025-01-06 | Christopher Nixon Cox | Director | A | +25,236 deriv. | — |
| 2024-07-11 | Adam Savitz | CHIEF MEDICAL OFFICER | Buy | +15,000 | +$190.83K |
| 2024-05-22 | Jr. Michael Conick Hanley | Chief Operating Officer | A | +188,000 deriv. | — |
| 2024-04-01 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | Buy | +6,150 | +$100.63K |
| 2024-03-12 | Maha Radhakrishnan | Director | A | +32,164 deriv. | — |
| 2024-03-06 | Apeiron Investment Group Ltd. | — | C | +2,779,617 | — |
| 2024-03-05 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | A | +19,153 | — |
| 2024-03-05 | Adam Savitz | CHIEF MEDICAL OFFICER | A | +73,000 deriv. | — |
| 2024-03-05 | Amit Etkin | PRESIDENT AND CEO | A | +34,711 | — |
| 2024-02-08 | Chimera Investment LLC | 10%+ Owner | MIXED | +14,831,028 | +$38.40M |
| 2024-02-07 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | Buy | +1,563 | +$25.01K |
| 2024-02-07 | Amit Etkin | PRESIDENT AND CEO | MIXED | +14,902 | +$50.00K |
| 2024-02-07 | Po Yu (Jeff) Chen | Director | C | +47,709 | — |
| 2024-02-07 | Gwill York | Director | C | +23,917 | — |
| 2024-02-07 | Christopher Nixon Cox | Director | C | +715,653 | — |
| 2024-02-07 | Adam Savitz | CHIEF MEDICAL OFFICER | MIXED | +24,851 | +$272.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Amit Etkin | PRESIDENT AND CEO | 833,949 | $18.44M |
| Christopher Nixon Cox | Director | 588,898 | $13.02M |
| Nicholas Conrad Smith | PRESIDENT AND CFO | 79,060 | $1.75M |
| Adam Savitz | CHIEF MEDICAL OFFICER | 36,920 | $816.30K |
| Gwill York | Director | 23,917 | $528.80K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANRO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.